Home News

First half 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Mon, 27/07/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI receives the FDA’s approval of Risvan® as a treatment for schizophrenia
Madrid – 2 April, 2024 – Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the U.S. Food and Drug...
4 min
02/04/2024
ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and...
Madrid, 12 March 2024 Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, ROVI), informs of the agreement that has been concluded with...
3 min
12/03/2024
Full Year 2023 Results Press Release
ROVI ACHIEVED OPERATING REVENUE GROWTH OF 1% IN THE FIRST POST-PANDEMIC YEAR Operating revenue increased 1% to 829.5 million euros in...
4 min
27/02/2024